Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.

Helena A. Yu, Melissa L. Johnson, Nisha Mohindra et al.|Journal of Clinical Oncology|2026

Cited by 1